-
1
-
-
0028955388
-
Epidermal growth factor-related peptides and their receptors in human malignancies
-
Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19:183-232.
-
(1995)
Crit Rev Oncol Hematol
, vol.19
, pp. 183-232
-
-
Salomon, D.S.1
Brandt, R.2
Ciardiello, F.3
Normanno, N.4
-
2
-
-
72049103970
-
Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry
-
Liu D., Jiang J., Hu P., Tan F., Wang Y. Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B 2009, 877(30):3781-3786.
-
(2009)
J Chromatogr B
, vol.877
, Issue.30
, pp. 3781-3786
-
-
Liu, D.1
Jiang, J.2
Hu, P.3
Tan, F.4
Wang, Y.5
-
3
-
-
84873066370
-
Icotinib, a potent and selective oral EGFR inhibitor, is well tolerated and active in patients with NSCLC: results from a phase I/II trial
-
Zhao Q., Zhang L., Jiang J., Xu L., Shentu J., Liu D., et al. Icotinib, a potent and selective oral EGFR inhibitor, is well tolerated and active in patients with NSCLC: results from a phase I/II trial. 13th world conference on lung cancer (WCLC) 2009.
-
(2009)
13th world conference on lung cancer (WCLC)
-
-
Zhao, Q.1
Zhang, L.2
Jiang, J.3
Xu, L.4
Shentu, J.5
Liu, D.6
-
4
-
-
79960035905
-
Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors
-
AUGUST 2
-
Zhao Q., Shentu J., Xu N., Zhou J., Yang G., Yao Y., et al. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer 2011, 73(August (2)):195-202.
-
(2011)
Lung Cancer
, vol.73
, pp. 195-202
-
-
Zhao, Q.1
Shentu, J.2
Xu, N.3
Zhou, J.4
Yang, G.5
Yao, Y.6
-
5
-
-
84859428976
-
A phase I/IIa study of icotinib hydrochloride, a novel oral EGFR-TKI, to evaluate its safety, tolerance, and preliminary efficacy in advanced NSCLC patients in China
-
Zhao Q., Zhou J., Shentu J., Xu N., Tan F. A phase I/IIa study of icotinib hydrochloride, a novel oral EGFR-TKI, to evaluate its safety, tolerance, and preliminary efficacy in advanced NSCLC patients in China. ASCO 2010 meeting report 2010.
-
(2010)
ASCO 2010 meeting report
-
-
Zhao, Q.1
Zhou, J.2
Shentu, J.3
Xu, N.4
Tan, F.5
-
6
-
-
84873067615
-
-
ClinicalTrials.gov. Safety and efficacy study of Icotinb in non-small cell lung cancer (NSCLC) patients (ICOGEN). ClinicalTrials.gov identifier . Available at: [accessed January 16, 2011].
-
ClinicalTrials.gov. Safety and efficacy study of Icotinb in non-small cell lung cancer (NSCLC) patients (ICOGEN). ClinicalTrials.gov identifier . Available at: [accessed January 16, 2011]. http://clinicaltrials.gov/.
-
-
-
-
7
-
-
83455209248
-
A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN)
-
SUPPL. [abstr 7522]
-
Sun Y., Shi Y., Zhang L., Liu X., Zhou C., Zhang L., et al. A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN). J Clin Oncol 2011, 29(Suppl.). [abstr 7522].
-
(2011)
J Clin Oncol
, vol.29
-
-
Sun, Y.1
Shi, Y.2
Zhang, L.3
Liu, X.4
Zhou, C.5
Zhang, L.6
-
8
-
-
85040746919
-
A randomized, double-blind phase III study of Icotinib versus Gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy(ICOGEN)
-
[abstr O10.06]
-
Sun Y., Shi Y., Zhang L., Liu X., Zhou C., Wang D., et al. A randomized, double-blind phase III study of Icotinib versus Gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy(ICOGEN). 14th world conference on lung cancer (WCLC 2011, [abstr O10.06].
-
(2011)
14th world conference on lung cancer (WCLC
-
-
Sun, Y.1
Shi, Y.2
Zhang, L.3
Liu, X.4
Zhou, C.5
Wang, D.6
-
9
-
-
80052794272
-
Metabolite characterization of a novel anti-cancer agent, icotinib, in humans through liquid chromatography/quadrupole time-of-flight tandem mass spectrometry
-
Liu D., Jiang J., Zhang L., Tan F., Wang Y., Hu P. Metabolite characterization of a novel anti-cancer agent, icotinib, in humans through liquid chromatography/quadrupole time-of-flight tandem mass spectrometry. Rapid Commun Mass Spectrom 2011, 25(15):2131-2140.
-
(2011)
Rapid Commun Mass Spectrom
, vol.25
, Issue.15
, pp. 2131-2140
-
-
Liu, D.1
Jiang, J.2
Zhang, L.3
Tan, F.4
Wang, Y.5
Hu, P.6
-
10
-
-
79961057151
-
Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer
-
Ren G., Zhao Y., Zhu Y. Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer. Chin Med J 2011, 124(1):19-25.
-
(2011)
Chin Med J
, vol.124
, Issue.1
, pp. 19-25
-
-
Ren, G.1
Zhao, Y.2
Zhu, Y.3
-
12
-
-
0037429737
-
Epidermal growth factor receptor: mechanisms of activation and signaling
-
Jorissen R.N., Walker F., Pouliot N., Garrett T.P., Ward C.W., Burgess A.W. Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res 2003, 284:31-53.
-
(2003)
Exp Cell Res
, vol.284
, pp. 31-53
-
-
Jorissen, R.N.1
Walker, F.2
Pouliot, N.3
Garrett, T.P.4
Ward, C.W.5
Burgess, A.W.6
-
13
-
-
0037229076
-
Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage
-
Kari C., Chan T.O., Quadros M.R., Rodeck U. Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 2003, 63:1-5.
-
(2003)
Cancer Res
, vol.63
, pp. 1-5
-
-
Kari, C.1
Chan, T.O.2
Quadros, M.R.3
Rodeck, U.4
-
15
-
-
0028142387
-
A specific inhibitor of the epidermal growth factor receptor tyrosine kinase
-
Fry D.W., Kraker A.J., McMichael A., Ambroso L.A., Nelson J.M., Leopold W.R., et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994, 265:1093-1095.
-
(1994)
Science
, vol.265
, pp. 1093-1095
-
-
Fry, D.W.1
Kraker, A.J.2
McMichael, A.3
Ambroso, L.A.4
Nelson, J.M.5
Leopold, W.R.6
-
16
-
-
9844235351
-
Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines
-
Traxler P., Bold G., Frei J., Lang M., Lydon N., Mett H., et al. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. J Med Chem 1997, 40:3601-3616.
-
(1997)
J Med Chem
, vol.40
, pp. 3601-3616
-
-
Traxler, P.1
Bold, G.2
Frei, J.3
Lang, M.4
Lydon, N.5
Mett, H.6
-
17
-
-
0034788453
-
Tyrosine kinase inhibitors: from rational design to clinical trials
-
Traxler P., Bold G., Buchdunger E., Caravatti G., Furet P., Manley P., et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001, 21:499-512.
-
(2001)
Med Res Rev
, vol.21
, pp. 499-512
-
-
Traxler, P.1
Bold, G.2
Buchdunger, E.3
Caravatti, G.4
Furet, P.5
Manley, P.6
-
18
-
-
66949133946
-
Toxicity of anti-EGFR therapy in common cancers
-
Clinical Efficacy
-
Harandi A., Zaidi A.S., Stocker A.M., Laber D.A., Clinical Efficacy Toxicity of anti-EGFR therapy in common cancers. J Oncol 2009, 2009:567486.
-
(2009)
J Oncol
, vol.2009
, pp. 567486
-
-
Harandi, A.1
Zaidi, A.S.2
Stocker, A.M.3
Laber, D.A.4
-
19
-
-
77953930730
-
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
-
Maemondo M., Inoue A., Kobayashi K., Sugawara S., Qizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
-
(2010)
N Engl J Med
, vol.362
, pp. 2380-2388
-
-
Maemondo, M.1
Inoue, A.2
Kobayashi, K.3
Sugawara, S.4
Qizumi, S.5
Isobe, H.6
-
20
-
-
0012381722
-
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial)
-
Fukuoka M., Yano S., Giaccone G., Takagawa K., Douillard J.Y., Nishiwaki Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial). J Clin Oncol 2003, 21:2237-2246.
-
(2003)
J Clin Oncol
, vol.21
, pp. 2237-2246
-
-
Fukuoka, M.1
Yano, S.2
Giaccone, G.3
Takagawa, K.4
Douillard, J.Y.5
Nishiwaki, Y.6
-
21
-
-
4344646459
-
Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer
-
Perez-Soler R., Chachoua A., Hammond L.A., Rowinsky E.K., Huberman M., Karp D., et al. Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J Clin Oncol 2004, 22:3238-3247.
-
(2004)
J Clin Oncol
, vol.22
, pp. 3238-3247
-
-
Perez-Soler, R.1
Chachoua, A.2
Hammond, L.A.3
Rowinsky, E.K.4
Huberman, M.5
Karp, D.6
-
22
-
-
0142055937
-
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with nonsmall cell lung cancer: a randomized trial
-
Kris M.G., Natale R.B., Herbst R.S., Lynch T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with nonsmall cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158.
-
(2003)
JAMA
, vol.290
, pp. 2149-2158
-
-
Kris, M.G.1
Natale, R.B.2
Herbst, R.S.3
Lynch, T.J.4
Prager, D.5
Belani, C.P.6
-
23
-
-
56249109644
-
Gefetinib versus docetaxel in previously treated non-small-cell lung caner (INTEREST): a randomised phase III trial
-
Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefetinib versus docetaxel in previously treated non-small-cell lung caner (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
-
(2008)
Lancet
, vol.372
, pp. 1809-1818
-
-
Kim, E.S.1
Hirsh, V.2
Mok, T.3
Socinski, M.A.4
Gervais, R.5
Wu, Y.L.6
-
24
-
-
84873064472
-
Phase III, randomized, open-label, first-line study of gefitinib(G) versus caboplatin/paclitaxel (C/P) in selected patients(pts) with advanced non-small-cell lung cancer(NSCLC) (IPASS): evaluation of recruits in Japan
-
Ohe Y., Ichinose Y., Nishiwaki Y., Yamamoto N., Negoro S., Duffield E., et al. Phase III, randomized, open-label, first-line study of gefitinib(G) versus caboplatin/paclitaxel (C/P) in selected patients(pts) with advanced non-small-cell lung cancer(NSCLC) (IPASS): evaluation of recruits in Japan. J Clin Oncol 2009, 27(Suppl.):8044.
-
(2009)
J Clin Oncol
, vol.27
, Issue.SUPPL.
, pp. 8044
-
-
Ohe, Y.1
Ichinose, Y.2
Nishiwaki, Y.3
Yamamoto, N.4
Negoro, S.5
Duffield, E.6
-
25
-
-
27844589038
-
Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy
-
Qin B., Chen X., Zhu J., Pei D. Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy. Cell Res 2005, 15:212-217.
-
(2005)
Cell Res
, vol.15
, pp. 212-217
-
-
Qin, B.1
Chen, X.2
Zhu, J.3
Pei, D.4
-
27
-
-
3042634240
-
Tyrosine kinase inhibitors in cancer therapy
-
Madhusudan S., Ganesan T.S. Tyrosine kinase inhibitors in cancer therapy. Clin Biochem 2004, 37:618-635.
-
(2004)
Clin Biochem
, vol.37
, pp. 618-635
-
-
Madhusudan, S.1
Ganesan, T.S.2
|